Clinical trial · Observational
Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients
Metaxa's Thromboprophylaxis Program in Oncological & Surgical Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
During MeTHOS study will be collected Real World Data the clinical practice regarding Thromboprophylaxis in high thrombotic risk solid tumors patients undergoing surgical and /or chemotherapeutical treatment, for one year following the protocol initiation date. Specifically focus will be on the following: * Number of thrombotic events * Anti-thrombotic management dosage \& duration * Any bleedings related to anticoagulation * Patients' adherence and compliance
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Cancer | Malignant Solid Neoplasm | ALIAS | 0.90 |
| Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low Molecular Weight Heparin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Number of thrombotic events
- timeFrame
- Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)
- description
- Measure the number of thrombotic events in the population
- measure
- Number of bleedings related to anticoagulation
- timeFrame
- Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)
- description
- Measure the number of observed bleeding events caused by the anticoagulation treatment
Secondary outcomes (4)
- measure
- Anticoagulation drug dosage
- timeFrame
- Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who were diagnosed with histological confirmed high thrombotic risk cancers (GI, thoracic, gynecologic and genitourinary) undergoing surgery 2. Age ≥ 18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 4. Life expectancy \>6 months 5. Signed informed consent Exclusion Criteria 1. Patients who were not diagnosed with histological confirmed high thrombotic risk cancers (GI, thoracic, gynecologic and genitourinary) undergoing surgery 2. Age \< 18 years 3. ECOG performance status \>2 4. Life expectancy \<6 months 5. Not signed informed consent
References
Publications (1)
- DERIVEDXynogalos S, Simeonidis D, Papageorgiou G, Pouliakis A, Charalambakis N, Lianos E, Mazlimoglou E, Liatsos AN, Kosmas C, Ziras N. Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study. Support Care Cancer. 2022 Aug;30(8):6973-6984. doi: 10.1007/s00520-022-07096-1. Epub 2022 May 12. PMID 35552827